Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.

@article{Mead1985ChronicLT,
  title={Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.},
  author={R. Mead and D. Keefe and R. Kates and R. Winkle},
  journal={The American journal of cardiology},
  year={1985},
  volume={55 1},
  pages={
          72-8
        }
}
  • R. Mead, D. Keefe, +1 author R. Winkle
  • Published 1985
  • Medicine
  • The American journal of cardiology
  • Chronic premature ventricular complexes (PVCs) have been effectively suppressed by oral lorcainide as reported in previous short-term studies. The plasma level-effect relation of lorcainide may be affected by the possible cardioactivity of norlorcainide, a metabolite that accumulates after repeated oral doses. This study evaluated the long-term efficacy of lorcainide in suppressing chronic symptomatic PVCs, and examined the relation of arrhythmia suppression to plasma concentrations of… CONTINUE READING
    10 Citations

    Topics from this paper

    Recent antiarrhythmic drugs.
    • 13
    The use of drugs in renal failure.
    • 20

    References

    SHOWING 1-10 OF 14 REFERENCES
    Lorcainide; II. Plasma concentration‐effect relationship
    • 60
    Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.
    • 47